AU2019221798A1 - Gene therapy of the faah pseudogene - Google Patents

Gene therapy of the faah pseudogene Download PDF

Info

Publication number
AU2019221798A1
AU2019221798A1 AU2019221798A AU2019221798A AU2019221798A1 AU 2019221798 A1 AU2019221798 A1 AU 2019221798A1 AU 2019221798 A AU2019221798 A AU 2019221798A AU 2019221798 A AU2019221798 A AU 2019221798A AU 2019221798 A1 AU2019221798 A1 AU 2019221798A1
Authority
AU
Australia
Prior art keywords
faah
inhibitor
pain
sequence
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019221798A
Other languages
English (en)
Inventor
James John COX
Devjit SRIVASTAVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of AU2019221798A1 publication Critical patent/AU2019221798A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01004—Amidase (3.5.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019221798A 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene Abandoned AU2019221798A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1802326.7A GB201802326D0 (en) 2018-02-13 2018-02-13 Gene therapy
GB1802326.7 2018-02-13
PCT/GB2019/050368 WO2019158909A1 (en) 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene

Publications (1)

Publication Number Publication Date
AU2019221798A1 true AU2019221798A1 (en) 2020-09-03

Family

ID=61731413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019221798A Abandoned AU2019221798A1 (en) 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene

Country Status (8)

Country Link
US (1) US12241066B2 (https=)
EP (1) EP3752608B1 (https=)
JP (1) JP2021512929A (https=)
CN (1) CN112088214A (https=)
AU (1) AU2019221798A1 (https=)
CA (1) CA3090617A1 (https=)
GB (1) GB201802326D0 (https=)
WO (1) WO2019158909A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
WO2022020756A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
CN119932015B (zh) * 2024-12-20 2025-11-25 中国科学院生物物理研究所 一种lncATRIG抑制剂及其在制备治疗胶质瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
US20070088073A1 (en) * 2005-10-19 2007-04-19 Allergan, Inc. Method for treating pain
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2670245B1 (en) 2011-02-04 2015-09-09 The Scripps Research Institute Alpha-ketoheterocycles and methods of making and using
KR102079404B1 (ko) 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제

Also Published As

Publication number Publication date
GB201802326D0 (en) 2018-03-28
CN112088214A (zh) 2020-12-15
US20210002648A1 (en) 2021-01-07
EP3752608B1 (en) 2026-03-18
EP3752608A1 (en) 2020-12-23
JP2021512929A (ja) 2021-05-20
US12241066B2 (en) 2025-03-04
WO2019158909A1 (en) 2019-08-22
CA3090617A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
Ge et al. Increased miR-21-3p in injured brain microvascular endothelial cells after traumatic brain injury aggravates blood–brain barrier damage by promoting cellular apoptosis and inflammation through targeting MAT2B
JP7851349B2 (ja) Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド
JP6234370B2 (ja) 神経変性障害におけるマイクロｒｎａ
US20200032257A1 (en) Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
US20180155414A1 (en) Targeting Apolipoprotein E (APOE) in Neurologic Disease
EP3752608B1 (en) Gene therapy of the faah pseudogene
US20210130447A1 (en) Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy
Li et al. Correlation between tumor necrosis factor alpha mRNA and microRNA-155 expression in rat models and patients with temporal lobe epilepsy
WO2023004049A1 (en) Unc13a antisense oligonucleotides
BR112021010793A2 (pt) Métodos de detecção, prevenção, reversão e tratamento de doenças neurológicas
WO2013134403A1 (en) Method of treating neurodegenerative diseases with microrna regulators
WO2024155986A2 (en) Unc13a antisense oligonucleotides
WO2014202973A1 (en) Agonists of ddah1 for treating endothelial dysfunction
US10947538B2 (en) Allele-specific gene suppression
Arnanz et al. Fatty acid amide hydrolase gene inactivation induces hetero‐cellular potentiation of microglial function in the 5xFAD mouse model of Alzheimer's disease
WO2025186229A2 (en) Use of mirnas for the prognosis of stroke patients and as targets for the treatment of stroke.
Franklin et al. SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential
Cao et al. Curcumin Regulates Microglia Polarization to Alleviate Ischemic Stroke by Targeting microRNA‐205‐5p/Kruppel‐Like Factor 2 (KLF2)/Activating Transcription Factor 2 (ATF2) Axis
Hu et al. MiR-30b-5p alleviates trigeminal neuralgia induced by chronic constriction injury of the infraorbital nerve by regulating the voltage-gated sodium channel Nav1. 3 in rats
EP2134842A2 (en) Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
Mairet-Coello¹ et al. mechanism that protects the epileptic brain from further
CN118475695A (zh) Unc13a反义寡核苷酸

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application